105 related articles for article (PubMed ID: 9378246)
41. The role of nitric oxide in the development of opioid withdrawal induced by naloxone after acute treatment with mu- and kappa-opioid receptor agonists.
Capasso A; Sorrentino L; Pinto A
Eur J Pharmacol; 1998 Oct; 359(2-3):127-31. PubMed ID: 9832382
[TBL] [Abstract][Full Text] [Related]
42. Roles of mu, delta and kappa opioid receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot-plate analgesia in the mouse.
Porreca F; Mosberg HI; Hurst R; Hruby VJ; Burks TF
J Pharmacol Exp Ther; 1984 Aug; 230(2):341-8. PubMed ID: 6086883
[TBL] [Abstract][Full Text] [Related]
43. Differential effects of two kappa-opiate agonists, U-50,488H and U-69,593, on the binding of 3H-(3-MeHis2) thyrotropin-releasing hormone to rat spinal cord and amygdala membranes.
Rahmani NH; Gulati A; Bhargava HN
Pharmacology; 1991; 43(3):156-62. PubMed ID: 1663623
[TBL] [Abstract][Full Text] [Related]
44. Effects of ACEA-1328, a NMDA receptor/glycine site antagonist, on U50,488H-induced antinociception and tolerance.
Lutfy K; Doan P; Nguyen M; Weber E
Eur J Pharmacol; 1999 Nov; 384(1):1-5. PubMed ID: 10611412
[TBL] [Abstract][Full Text] [Related]
45. Contralateral, ipsilateral and bilateral treatments with the kappa-opioid receptor agonist U-50,488H in mononeuropathic rats.
Bileviciute-Ljungar I; Spetea M
Eur J Pharmacol; 2004 Jun; 494(2-3):139-46. PubMed ID: 15212967
[TBL] [Abstract][Full Text] [Related]
46. Chronic cocaine injections attenuate behavioral response of kappa-opioid receptors to U-50,488H agonist.
Kudryavtseva NN; Gerrits MA; Alekseenko OV; Van Ree JM
Bull Exp Biol Med; 2005 Sep; 140(3):320-2. PubMed ID: 16307048
[TBL] [Abstract][Full Text] [Related]
47. dextro- and levo-morphine attenuate opioid delta and kappa receptor agonist produced analgesia in mu-opioid receptor knockout mice.
Wu HE; Sun HS; Terashivili M; Schwasinger E; Sora I; Hall FS; Uhl GR; Tseng LF
Eur J Pharmacol; 2006 Feb; 531(1-3):103-7. PubMed ID: 16445907
[TBL] [Abstract][Full Text] [Related]
48. Role of the nitric oxide pathway in kappa-opioid-induced hypothermia in rats.
Benamar K; Geller EB; Adler MW
J Pharmacol Exp Ther; 2002 Oct; 303(1):375-8. PubMed ID: 12235273
[TBL] [Abstract][Full Text] [Related]
49. Evidence for the role of nitric oxide in kappa-opiate tolerance in mice.
Thorat SN; Reddy PL; Bhargava HN
Brain Res; 1993 Sep; 621(1):171-4. PubMed ID: 7693300
[TBL] [Abstract][Full Text] [Related]
50. Modulation of free intracellular calcium levels [(Ca++)i] in brain and spinal cord of morphine-tolerant rats and mice.
Welch SP; Bass PP
Pharmacol Biochem Behav; 1995 May; 51(1):57-63. PubMed ID: 7617733
[TBL] [Abstract][Full Text] [Related]
51. Functional interaction among opioid receptor types: up-regulation of mu- and delta-opioid receptor functions after repeated stimulation of kappa-opioid receptors.
Khotib J; Narita M; Suzuki M; Yajima Y; Suzuki T
Neuropharmacology; 2004 Mar; 46(4):531-40. PubMed ID: 14975677
[TBL] [Abstract][Full Text] [Related]
52. Modulation of kappa-opioid receptor mediated tolerance in the guinea-pig ileum by chronic co-administration of dihydropyridines.
Garaulet JV; Laorden ML; Milanés MV
Naunyn Schmiedebergs Arch Pharmacol; 1996 Jun; 354(1):72-9. PubMed ID: 8832591
[TBL] [Abstract][Full Text] [Related]
53. Attenuation of the antinociceptive action of the selective kappa-opioid receptor agonist, U-50,488H by ICS-205-930.
Ho BY; Takemori AE
Eur J Pharmacol; 1990 Mar; 178(3):371-3. PubMed ID: 2160372
[TBL] [Abstract][Full Text] [Related]
54. Limbic brain structures are important sites of kappa-opioid receptor-mediated actions in the rat: a [14C]-2-deoxyglucose study.
Ableitner A; Herz A
Brain Res; 1989 Jan; 478(2):326-36. PubMed ID: 2538203
[TBL] [Abstract][Full Text] [Related]
55. Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal.
Simonin F; Valverde O; Smadja C; Slowe S; Kitchen I; Dierich A; Le Meur M; Roques BP; Maldonado R; Kieffer BL
EMBO J; 1998 Feb; 17(4):886-97. PubMed ID: 9463367
[TBL] [Abstract][Full Text] [Related]
56. L-type Ca2+ channel modulation by dihydropyridines potentiates kappa-opioid receptor agonist induced acute analgesia and inhibits development of tolerance in rats.
Gullapalli S; Ramarao P
Neuropharmacology; 2002 Mar; 42(4):467-75. PubMed ID: 11955518
[TBL] [Abstract][Full Text] [Related]
57. Spinal kappa-opioid system plays an important role in suppressing morphine withdrawal syndrome in the rat.
Cui CL; Wu LZ; Han JS
Neurosci Lett; 2000 Dec; 295(1-2):45-8. PubMed ID: 11078933
[TBL] [Abstract][Full Text] [Related]
58. Withdrawal contractures of guinea-pig isolated ileum after acute activation of kappa-opioid receptors.
Morrone LA; Romanelli L; Amico MC; Valeri P
Br J Pharmacol; 1993 May; 109(1):48-52. PubMed ID: 8388301
[TBL] [Abstract][Full Text] [Related]
59. Effect of repeated administration of TRK-820, a kappa-opioid receptor agonist, on tolerance to its antinociceptive and sedative actions.
Suzuki T; Izumimoto N; Takezawa Y; Fujimura M; Togashi Y; Nagase H; Tanaka T; Endoh T
Brain Res; 2004 Jan; 995(2):167-75. PubMed ID: 14672806
[TBL] [Abstract][Full Text] [Related]
60. Streptozotocin-induced diabetes selectively alters the potency of analgesia produced by mu-opioid agonists, but not by delta- and kappa-opioid agonists.
Kamei J; Ohhashi Y; Aoki T; Kawasima N; Kasuya Y
Brain Res; 1992 Feb; 571(2):199-203. PubMed ID: 1319265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
